Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd edition)

Chest

Volumn 132, Issue 3 SUPPL., 2007, Pages 56S-68S

  Gray, Jhanelle ^a   Mao, Jenny T ^b   Szabo, Eva ^c   Kelley, Michael ^d   Kurie, Jonathan ^e   Bepler, Gerold ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d DUKE CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acetyl salicylic acid; Apoptosis; Biomarkers; Chemoprevention; Cyclooxygenase 2 inhibitors; Lung cancer; Proliferation; Protein kinase C; Selenium; Signal transduction pathways; Tyrosine kinase inhibitors; Vitamin A; Vitamin E

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BETA CAROTENE; ISOTRETINOIN; RETINOL; ANTINEOPLASTIC AGENT;

CANCER MORTALITY; CANCER RISK; CHEMOPROPHYLAXIS; CIGARETTE SMOKING; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG DYSPLASIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; UNITED STATES; ARTICLE; EVIDENCE BASED MEDICINE; LUNG TUMOR; PHASE 3 CLINICAL TRIAL;

ACETYLCYSTEINE; ALPHA-TOCOPHEROL; ANTICARCINOGENIC AGENTS; ASPIRIN; BETA CAROTENE; CHEMOPREVENTION; CLINICAL TRIALS, PHASE III; EVIDENCE-BASED MEDICINE; HUMANS; ISOTRETINOIN; LUNG NEOPLASMS; UNITED STATES; VITAMIN A;

EID: 34848819086     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1348     Document Type: Article

References (120)

1. Cancer facts and figures-2007. Atlanta, GA: American Cancer Society, 2007; 1-54
2. Cigarette smoking among adults-United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 54:509-513
3. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323-329
4. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-454
5. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963-968
6. Cancer facts and figures-1995. Atlanta, GA: American Cancer Society, 1995
7. Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91:675-690
8. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; (4):CD000165
9. Stead L, Lancaster T. Group behavior therapy programmes for smoking cessation. Cochrane Database Syst Rev 2002; (3):CD001007
10. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; (3):CD000146
11. Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care 2000; 45:1200-1262
12. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update; Health Education Authority. Thorax 2000; 55:987-999
13. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195-1202
14. Henningfield JE, Fant RV, Buchhalter AR, et al. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005; 55:281-299
15. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47-55
16. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56-63
17. White AR, Rampes H, Ernst E. Acupuncture for smoking cessation. Cochrane Database Syst Rev 2002; (2):CD000009
18. The Surgeon General's 1990 report on the health benefits of smoking cessation. Executive summary. MMWR Recomm Rep 1990; 39:i-xv, 1-12
19. Sendowski M, Bepler G. Chemoprevention for lung cancer. Oncol Spectr 2002; 3:116-126
20. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278:1073-1077
21. Khuri FR, Lippman SM. Lung cancer chemoprevention. Semin Surg Oncol 2000; 18:100-105
22. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005; 23:3175-3185
23. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: a study of 684 proved cases. J Am Med Assoc 1950; 143:329-336
24. Levin ML, Goldstein H, Gerhardt PR. Cancer and tobacco smoking: a preliminary report. J Am Med Assoc 1950; 143:336-338
25. Doll R, Hill AB. Smoking and carcinoma of the lung: preliminary report. BMJ 1950; 2:739-748
26. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits: a preliminary report. BMJ 1954; 4877:1451-1455
27. Burney LE. Excessive cigarette smoking. Public Health Rep 1957; 72:786
28. Burney LE. Smoking and lung cancer: a statement of the Public Health Service. JAMA 1959; 171:1829-1837
29. Cornfield J, Haenszel W, Hammond EC, et al. Smoking and lung cancer: recent evidence and a discussion of some questions. J Natl Cancer Inst 1959; 22:173-203
30. Winterhalder RC, Hirsch FR, Kotantoulas GK, et al. Chemoprevention of lung cancer: from biology to clinical reality. Ann Oncol 2004; 15:185-196
31. Burns DM, Shanks TG, Choi W, et al. The American Cancer Society Prevention Study I: 12-year follow-up of 1 million men and women. In: National Cancer Institute, Smoking and Tobacco Control, Monograph 8: changes in cigarette-related risks and their implication for prevention and control. Washington, DC: National Institutes of Health, 1997; 113-304; NIH Publication No. 97-4213
32. Breuer RH, Pasic A, Smit EF, et al. The natural course of preneoplastic lesions in bronchial epithelium. Clin Cancer Res 2005; 11:537-543
33. Wistuba II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999; 18:643-650
34. Hoshino H, Shibuya K, Chiyo M, et al. Biological features of bronchial squamous dysplasia followed up by autofluorescence bronchoscopy. Lung Cancer 2004; 46:187-196
35. Saccomanno G, Archer VE, Auerbach O, et al. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974; 33:256-270
36. Kennedy TC, Franklin WA, Prindiville SA, et al. High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. Lung Cancer 2005; 49:187-191
37. Prindiville SA, Byers T, Hirsch FR, et al. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 2003; 12:987-993
38. Frost JK, Ball WC Jr, Levin ML, et al. Sputum cytopathology: use and potential in monitoring the workplace environment by screening for biological effects of exposure. J Occup Med 1986; 28:692-703
39. Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998; 90:1335-1345
40. Blumberg J, Block C. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland. Nutr Rev 1994; 52:242-245
41. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145-1149
42. Lee IM, Cook NR, Manson JE, et al. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999; 91:2102-2106
43. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293:1338-1347
44. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study; a randomized controlled trial. JAMA 2005; 294:56-65
45. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-1155
46. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93:605-618
47. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer: for the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92:977-986
48. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ (Clin Res Ed) 1988; 296:313-316
49. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321:129-135
50. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study; a randomized controlled trial. JAMA 2005; 294:47-55
51. Park IW, Wistuba II, Maitra A, et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 1999; 91:1863-1868
52. Kreitz S, Fackelmayer FO, Gerdes J, et al. The proliferation-specific human Ki-67 protein is a constituent of compact chromatin. Exp Cell Res 2000; 261:284-292
53. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000; 257:231-237
54. Schluter C, Duchrow M, Wohlenberg C, et al. The cell proliferation- associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993; 123:513-522
55. Maeshima Y, Kashihara N, Sugiyama H, et al. Antisense oligonucleotides to proliferating cell nuclear antigen and Ki-67 inhibit human mesangial cell proliferation. J Am Soc Nephrol 1996; 7:2219-2229
56. Kearsey SE, Maiorano D, Holmes EC, et al. The role of MCM proteins in the cell cycle control of genome duplication. Bioessays 1996; 18:183-190
57. Lei M, Tye BK. Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci 2001; 114:1447-1454
58. Labib K, Tercero JA, Diffley JF. Uninterrupted MCM2-7 function required for DNA replication fork progression. Science 2000; 288:1643-1647
59. Heimburger DC. Localized deficiencies of folic acid in aerodigestive tissues. Ann NY Acad Sci 1992; 669:87-95; discussion 95-86
60. Heimburger DC, Alexander CB, Birch R, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12: report of a preliminary randomized, double-blind intervention trial. JAMA 1988; 259:1525-1530
61. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochern 2000; 69:145-182
62. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56:4424-4429
63. Hasturk S, Kemp B, Kalapurakal SK, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 2002; 94:1023-1031
64. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7:861-867
65. West HY, Giarrita S, Livingston R, et al. Cyclooxygenase-2 (COX-2) overexpression by immunohistochemistry (IHC) is associated with more aggressive biological behavior of non-small cell lung cancer (NSCLC) tumors. Proc Am Soc Clin Oncol 2002; 21:1235a
66. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311
67. Arenberg DA, Polverini PJ, Kunkel SL, et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 1997; 62:554-562
68. Arenberg DA, Keane MP, DiGiovine B, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998; 102:465-472
69. White ES, Flaherty KR, Carskadon S, et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003; 9:853-860
70. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003; 4:431-436
71. Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 2005; 115:545-555
72. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13:35-48
73. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001; 276:20809-20812
74. Dohadwala M, Batra RK, Luo J, et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002; 277:50828-50833
75. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-336
76. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9:541-573
77. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370:61-65
78. Krysan K, Dalwadi H, Sharma S, et al. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 2004; 64:6359-6362
79. Krysan K, Merchant FH, Zhu L, et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 2004; 18:206-208
80. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000; 183:1-9
81. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. MoI Pathol 2001; 54:145-148
82. Franklin SL, Ferry RJ Jr, Cohen P. Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 2003; 88:900-907
83. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-924
84. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells, Immunol Today 1993; 14:335-338
85. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153:1697-1706
86. Beissert S, Hosoi J, Grabbe S, et al. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 1995; 154:1280-1286
87. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58:1208-1216
88. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164:361-370
89. Kisley LR, Barrett BS, Dwyer-Nield LD, et al. Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 2002; 23:1653-1660
90. Mao JT, Tsu IH, Dubinett SM, et al. Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res 2004; 10:6872-6878
91. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling, J Clin Invest 1996; 97:806-813
92. Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 1998; 19:1393-1400
93. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003; 17:1986-1995
94. Lam S, leRiche JC, McWilliams A, et al, A randomized phase lib trial of Pulmicort Turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004; 10:6502-6511
95. Mao JT, Roth MD, Serio KJ, et al. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin Cancer Res 2003; 9:5835-5841
96. Mao JT, Fishbein MC, Adams B, et al. Celecoxib decreases Ki-67 proliferative index in active smokers, Clin Cancer Res 2006; 12:314-320
97. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000; 343:1520-1528
98. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study; a randomized controlled trial; Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255
99. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102
100. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080
101. Zhuo H, Smith AH, Steinmaus C. Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev 2004; 13:771-778
102. van den Brandt PA, Goldbohm RA, van't Veer P, et al. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Res 1993; 53:4860-4865
103. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005; 97:94-102
104. Ghosh J. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 2004; 315:624-635
105. Reid ME, Duffield-Lillico AJ, Garland L, et al. Selenium supplementation and lung cancer incidence: an update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002; 11:1285-1291
106. Kensler T, Styczynski P, Groopman J, et al. Mechanisms of chemoprotection by oltipraz. J Cell Biochem Suppl 1992; 161:167-172
107. Kelley M, Folz RJ, Glaser EM, et al. Phase 1 chemoprevention trial of oltipraz in smokers [abstract]. Proc Am Soc Clin Oncol 2003; 22:92
108. Pendyala L, Schwartz G, Bolanowska-Higdon W, et al. Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity, Cancer Epidemiol Biomarkers Prev 2001; 10:269-272
109. Lam S, MacAulay C, Le Riche JC, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002; 94:1001-1009
110. Jarvis WD, Grant S. Protein kinase C targeting in antineoplastic treatment strategies, Invest New Drugs 1999; 17:227-240
111. Gescher A. Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol 1998; 31:721-728
112. Parker PJ. Inhibition of protein kinase C: do we, can we, and should we? Pharmacol Ther 1999; 82:263-267
113. Lantry LE, Zhang Z, Yao R, et al. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 2000; 21:113-116
114. Zhang Z, Wang Y, Lantry LE, et al. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf Oncogene 2003; 22:6257-6265
115. Gunning WT, Kramer PM, Lubet RA, et al. Chemoprevention of benzo (a) pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777. Clin Cancer Res 2003; 9:1927-1930
116. Mathe G, Gouveia J, Hercend T, et al. Correlation between precancerous bronchial metaplasia and cigarette consumption, and preliminary results of retinoid treatment. Cancer Detect Prev 1982; 5:461-466
117. Arnold AM, Browman GP, Levine MN, et al. The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer 1992; 65:737-743
118. McLarty J. Results of the Tyler Chemoprevention Trial: an intermediate endpoint study [abstract]. Proceedings of the 2nd International Conference: Antioxidant Vitamins and Beta-Carotene Disease Prevention 1994
119. Lee JS, Lippman SM, Benner SE, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12:937-945
120. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl)-retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000; 6:2973-2979